Nanthealth LLC (NYSE:NH) shares rose 2.2% on Thursday . The stock traded as high as $14.35 and last traded at $14.04, with a volume of 53,690 shares changing hands. The stock had previously closed at $13.74.

NH has been the subject of a number of research reports. Jefferies Group initiated coverage on shares of Nanthealth in a report on Monday, June 27th. They set a “buy” rating for the company. Canaccord Genuity initiated coverage on shares of Nanthealth in a report on Monday, June 27th. They set a “buy” rating and a $17.00 target price for the company. Cowen and Company began coverage on shares of Nanthealth in a report on Monday, June 27th. They set an “outperform” rating and a $19.00 target price for the company. FBR & Co began coverage on shares of Nanthealth in a research report on Monday, June 27th. They issued an “outperform” rating and a $18.00 price target for the company. Finally, First Analysis began coverage on shares of Nanthealth in a research report on Monday, June 27th. They issued an “overweight” rating and a $18.00 price target for the company. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $18.00.

The firm has a 50-day moving average price of $13.89 and a 200-day moving average price of $13.89. The stock’s market capitalization is $7.79 billion.

In related news, major shareholder Healthcare Solution Allscripts bought 714,286 shares of the stock in a transaction that occurred on Tuesday, June 7th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $10,000,004.00. Following the purchase, the insider now directly owns 15,000,000 shares of the company’s stock, valued at $210,000,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Patrick Soon-Shiong bought 357,143 shares of the stock in a transaction that occurred on Tuesday, June 7th. The stock was bought at an average price of $14.00 per share, with a total value of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.